Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Chocolate prices have been rising due to complications in the supply chain, but Penn State researchers have made a ...

In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the ...

Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...

Investing.com -- Intellia Therapeutics (NASDAQ:NTLA) stock fell 19% after the market close Wednesday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on the company’s Phase 3 ...

The news for the chocolate industry is a welcome development, as businesses and scientists grapple with crop shortages.

ETH Zurich scientists have created “MetaGraph,” a revolutionary DNA search engine that functions like Google for genetic data. By compressing global genomic datasets by a factor of 300, it allows ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

Chardan lowered the firm’s price target on Intellia Therapeutics (NTLA) to $48 from $60 and keeps a Buy rating on the shares. Intellia ...